Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lisinopril Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE known ✓ | P12821 | 8/20 | 0.98 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | F2 | P00734 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lisinopril Anhydrous SCHEMBL29047795 | 1.00 | ACE (0.98) | ACELMNASMN1; SMN2F2 | |
| Lisinopril Anhydrous SCHEMBL677321 | 1.00 | ACE (0.98) | ACELMNASMN1; SMN2F2 | |
| Lisinopril Anhydrous SCHEMBL1268274 | 1.00 | ACE (0.98) | ACELMNASMN1; SMN2F2 | |
| Lisinopril Anhydrous SCHEMBL31692087 | 1.00 | ACE (0.98) | ACELMNASMN1; SMN2F2 | |
| Lisinopril Anhydrous SCHEMBL542591 | 1.00 | ACE (0.98) | ACELMNASMN1; SMN2F2 | |
| Lisinopril Anhydrous SCHEMBL24062681 | 0.99 | ACE (1.00) | ACELMNASMN1; SMN2 | |
| Lisinopril Anhydrous SCHEMBL15680 | 0.99 | ACE (1.00) | ACELMNASMN1; SMN2 | |
| Lisinopril Anhydrous SCHEMBL156900 | 0.99 | ACE (1.00) | ACELMNASMN1; SMN2 | |
| Lisinopril Anhydrous SCHEMBL7268245 | 0.99 | ACE (1.00) | ACELMNASMN1; SMN2 | |
| Lisinopril Anhydrous SCHEMBL18712916 | 0.99 | ACE (1.00) | ACELMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 140 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2003022872-A2 | CRYSTAL FORM OF LISINOPRIL MONOHYDRATE | ASTRAZENECA AB (SE) | 2003-03-20 | — | — | WO | claimed |
| US-6468976-B1 | Monohydrate lisinopril | ASTRAZENECA AB (SE) | 2002-10-22 | — | — | US | claimed |
| US-6465615-B1 | DISSOLVING (LISINOPRIL) 1-(N2 -((S)-1-CARBOXY-3-PHENYLPROPYL)-L-LYSYL)-L-PROLINE IN WATER, ADDING ISOBUTANOL TO THE SOLUTION TO INDUCE CRYSTALLIZATION OF LISINOPRIL, ISOLATING AND DRYING THE CRYSTALS | ASTRAZENECA AB (SE) | 2002-10-15 | — | — | US | claimed |
| CN-110831576-B | Lisinopril compositions with ingestible event markers | 大冢制药株式会社 | 2024-07-16 | — | — | CN | disclosed |
| CN-117946209-A | Tumor targeting molecular probe and preparation method and application thereof | 江西中医药大学 | 2024-04-30 | — | — | CN | disclosed |
| EP-4346811-A1 | DUAL WNT SIGNALING PATHWAY INHIBITORS AND AMPK ACTIVATORS FOR TREATMENTS OF DISEASE | University of Maryland, Baltimore (US) | 2024-04-10 | — | — | EP | disclosed |
| US-11911480-B2 | Self-emulsifying composition of ω-3 fatty acid | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2024-02-27 | — | — | US | disclosed |
| US-20230405079-A1 | LISINOPRIL FORMULATIONS | HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT | 2023-12-21 | — | — | US | disclosed |
| US-11771733-B2 | Lisinopril formulations | Silvergate Pharmaceuticals, Inc. (US) | 2023-10-03 | — | — | US | disclosed |
| EP-3735963-B1 | SELF-EMULSIFYING COMPOSITION OF OMEGA-3 FATTY ACID | MOCHIDA PHARM CO LTD (JP) | 2023-09-13 | — | — | EP | disclosed |
| US-11684605-B2 | Lisinopril compositions with an ingestible event marker | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-06-27 | — | — | US | disclosed |
| WO-2003022872-A2 | CRYSTAL FORM OF LISINOPRIL MONOHYDRATE | ASTRAZENECA AB (SE) | 2003-03-20 | — | — | WO | disclosed |
| WO-2003022872-A2 | CRYSTAL FORM OF LISINOPRIL MONOHYDRATE | ASTRAZENECA AB (SE) | 2003-03-20 | — | — | WO | disclosed |
| WO-2003000716-A2 | PREPARATION AND USE OF AMORPHOUS LISINOPRIL | ASTRAZENECA AB (SE) | 2003-01-03 | — | — | WO | disclosed |
| US-6468976-B1 | Monohydrate lisinopril | ASTRAZENECA AB (SE) | 2002-10-22 | — | — | US | disclosed |
| US-6468976-B1 | Monohydrate lisinopril | ASTRAZENECA AB (SE) | 2002-10-22 | — | — | US | disclosed |
| US-6465615-B1 | DISSOLVING (LISINOPRIL) 1-(N2 -((S)-1-CARBOXY-3-PHENYLPROPYL)-L-LYSYL)-L-PROLINE IN WATER, ADDING ISOBUTANOL TO THE SOLUTION TO INDUCE CRYSTALLIZATION OF LISINOPRIL, ISOLATING AND DRYING THE CRYSTALS | ASTRAZENECA AB (SE) | 2002-10-15 | — | — | US | disclosed |
| US-6465615-B1 | DISSOLVING (LISINOPRIL) 1-(N2 -((S)-1-CARBOXY-3-PHENYLPROPYL)-L-LYSYL)-L-PROLINE IN WATER, ADDING ISOBUTANOL TO THE SOLUTION TO INDUCE CRYSTALLIZATION OF LISINOPRIL, ISOLATING AND DRYING THE CRYSTALS | ASTRAZENECA AB (SE) | 2002-10-15 | — | — | US | disclosed |
| US-6462174-B1 | ADMINISTERING LISINOPRIL AS HYPOTENSIVE AGENT; FAST MELTING | ASTRAZENECA AB (SE) | 2002-10-08 | — | — | US | disclosed |
| US-6458769-B1 | AMORPHOUS LISINOPRIL HAVING THE FORMULA (S)-1-(N.SUP.2 -(1-CARBOXY-3-PHENYLPROPYL))-L-LYSYL)-L-PROLINE, WHEREIN AMORPHOUS LISINOPRIL HAS A GLASS TRANSITION POINT (TG) WHEN DRY, MEASURED BY THERMAL MEHANICAL ANALYSIS | ASTRAZENECA AB (SE) | 2002-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11771733-B2 | Lisinopril formulations | REN, ACE, AGT | ACE 2/4885LMNA 174/4885SMN1; SMN2 1363/4885 |
| US-20230405079-A1 | LISINOPRIL FORMULATIONS | REN, ACE, AGT | ACE 2/4885LMNA 174/4885SMN1; SMN2 1363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.